Recent successes using CAR-T therapies have allowed investigators to expand their research efforts to a wide array of treatment possibilities for patients. Commercialization of autologous CAR-T cells brings about a host of challenges that biomanufacturers must solve in order to advance their production pipelines. As such, implementation of process control and automation, as well as assurance of supply, are key to consistent, high-quality CAR-T cell production. The use of functionally closed systems with the ability to monitor and control processes through online sensors can enable process control. Combined with the use of consistent, serum-free T-cell optimized media as well as low E&L, single-use consumables, this process can enable manufacturers to be well on their way to creating high-quality, potent therapies. Fill out the form below to get access and learn more about online monitoring for process control during the successful expansion of CAR-T cells.
Presenter:
Julia Hupfeld, Ph.D.
Julia Hupfeld has several years of experience in process development for cell-based therapeutics (ATMPs) and also worked on expansion and modulation of human mesenchymal stem cells on biomaterials in bioreactors during her Ph.D. studies at Roche. Julia holds a Ph.D. from the Technical University of Munich and an M.Sc. in Molecular Biotechnology from the University of Heidelberg and B.Sc. in Molecular Medicine from the University of Goettingen. She is a Solution Marketing Manager at Sartorius Advanced Therapies.